Last checked at 18 Oct 2023 15:30
GSK plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Emma Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.1980 | 474 | ||||
£15.1980 | 709 | ||||
£15.1980 | 1,178 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
2,361 £15.1980 | ||||
e) | Date of the transaction | 2023-10-16 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Hal Barron | |||
b) | Position/status | Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W2044 | |||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2023 on ADSs held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$37.0100 | 248 | ||||
$37.0100 | 391 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
639 $37.0100 | ||||
e) | Date of the transaction | 2023-10-16 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Diana Conrad | |||
b) | Position/status | Chief People Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.1980 | 68 | ||||
£15.1980 | 111 | ||||
£15.1980 | 214 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
393 £15.1980 | ||||
e) | Date of the transaction | 2023-10-16 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | James Ford | |||
b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.1980 | 82 | ||||
£15.1980 | 137 | ||||
£15.1980 | 208 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
427 £15.1980 | ||||
e) | Date of the transaction | 2023-10-16 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Sally Jackson | |||
b) | Position/status | SVP, Global Communications and CEO Office | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.1980 | 41 | ||||
£15.1980 | 64 | ||||
£15.1980 | 129 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
234 £15.1980 | ||||
e) | Date of the transaction | 2023-10-16 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Luke Miels | |||
b) | Position/status | Chief Commercial Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.1980 | 128 | ||||
£15.1980 | 233 | ||||
£15.1980 | 502 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
863 £15.1980 | ||||
e) | Date of the transaction | 2023-10-16 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Shobie Ramakrishnan | |||
b) | Position/status | Chief Digital and Technology Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W2044 | |||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2023 on ADSs held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$37.0100 | 23 | ||||
$37.0100 | 103 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
126 $37.0100 | ||||
e) | Date of the transaction | 2023-10-16 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | David Redfern | |||
b) | Position/status | President Corporate Development | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.1980 | 101 | ||||
£15.1980 | 154 | ||||
£15.1980 | 290 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
545 £15.1980 | ||||
e) | Date of the transaction | 2023-10-16 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Regis Simard | |||
b) | Position/status | President, Global Supply Chain | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.1980 | 76 | ||||
£15.1980 | 140 | ||||
£15.1980 | 233 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
449 £15.1980 | ||||
e) | Date of the transaction | 2023-10-16 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Phil Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.1980 | 59 | ||||
£15.1980 | 97 | ||||
£15.1980 | 152 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price | 308 £15.1980 | ||||
e) | Date of the transaction | 2023-10-16 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Deborah Waterhouse | |||
b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.1980 | 121 | ||||
£15.1980 | 102 | ||||
£15.1980 | 371 | ||||
d) | Aggregated information
| ||||
Aggregated volume Price |
594 £15.1980 | ||||
e) | Date of the transaction | 2023-10-16 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Tony Wood | |||
b) | Position/status | Chief Scientific Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s)
| Price(s) | Volume(s) | ||
£15.1980 | 176 |
| |||
| |||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2023-10-16 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Emma Walmsley | ||||
b) | Position/status | Chief Executive Officer | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GSK plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| ||||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
| ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | N/A (single transaction)
| ||||
e) | Date of the transaction | 2023-10-16 | ||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||